ECSP21052184A - Inhibidores de apol1 y sus métodos de uso - Google Patents

Inhibidores de apol1 y sus métodos de uso

Info

Publication number
ECSP21052184A
ECSP21052184A ECSENADI202152184A ECDI202152184A ECSP21052184A EC SP21052184 A ECSP21052184 A EC SP21052184A EC SENADI202152184 A ECSENADI202152184 A EC SENADI202152184A EC DI202152184 A ECDI202152184 A EC DI202152184A EC SP21052184 A ECSP21052184 A EC SP21052184A
Authority
EC
Ecuador
Prior art keywords
apol1
inhibitors
use methods
methods
ndkd
Prior art date
Application number
ECSENADI202152184A
Other languages
English (en)
Inventor
Jon H Come
Francois Denis
Kan-Nian Hu
Warren A Dorsch
Ales Medek
Leslie A Dakin
Martine Hamel
Brian Ledford
Tiansheng Wang
Yi Shi
Peter Rose
Faith Witkos
Kevin Gagnon
Suganthini S Nanthakumar
Elaine B Krueger
Olivier Nicolas
Jingrong Cao
Timothy J Senter
Muna Shrestha
Anne Fortier
Michael Brodney
Camil Sayegh
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ECSP21052184A publication Critical patent/ECSP21052184A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/46—Phosphinous acids R2=P—OH; Thiophosphinous acids; Aminophosphines R2-P-NH2 including R2P(=O)H; derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La descripción proporciona al menos una entidad seleccionada de compuestos de la fórmula (I), formas en estado sólido de ellos, composiciones que los comprenden y métodos que los usan, incluyendo el uso en el tratamiento de glomeruloesclerosis segmentaria focal (FSGS) y/o enfermedad renal no diabética (NDKD).
ECSENADI202152184A 2018-12-17 2021-07-15 Inhibidores de apol1 y sus métodos de uso ECSP21052184A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862780667P 2018-12-17 2018-12-17

Publications (1)

Publication Number Publication Date
ECSP21052184A true ECSP21052184A (es) 2021-08-31

Family

ID=69182627

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202152184A ECSP21052184A (es) 2018-12-17 2021-07-15 Inhibidores de apol1 y sus métodos de uso

Country Status (23)

Country Link
US (2) US11618746B2 (es)
EP (1) EP3897833A1 (es)
JP (1) JP2022515369A (es)
KR (1) KR20210116483A (es)
CN (1) CN113453760A (es)
AR (1) AR116913A1 (es)
AU (1) AU2019405477A1 (es)
BR (1) BR112021011564A2 (es)
CA (1) CA3121910A1 (es)
CL (1) CL2021001561A1 (es)
CO (1) CO2021009053A2 (es)
CR (1) CR20210383A (es)
DO (1) DOP2021000116A (es)
EC (1) ECSP21052184A (es)
IL (1) IL283592A (es)
JO (3) JOP20210129A1 (es)
MA (1) MA54538A (es)
MX (1) MX2021007152A (es)
PE (1) PE20212302A1 (es)
SG (1) SG11202105769XA (es)
TW (1) TW202039471A (es)
UY (1) UY38514A (es)
WO (1) WO2020131807A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210116483A (ko) 2018-12-17 2021-09-27 버텍스 파마슈티칼스 인코포레이티드 Apol1 억제제 및 그의 사용 방법
EP4097083A1 (en) * 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
TW202140459A (zh) * 2020-02-04 2021-11-01 美商維泰克斯製藥公司 Ａｐｏｌ１抑制劑之固體形式及其使用方法
US11801234B2 (en) 2020-03-06 2023-10-31 Vertex Pharmaceuticals Incorporated Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
AU2021333776A1 (en) 2020-08-26 2023-03-16 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
AU2022334580A1 (en) * 2021-08-26 2024-03-07 Vertex Pharmaceuticals Incorporated Solid forms of spirotricyclic apol1 inhibitors and methods of using same
WO2023101981A1 (en) * 2021-11-30 2023-06-08 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
WO2023154344A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
WO2023194895A1 (en) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1
WO2024040235A1 (en) * 2022-08-19 2024-02-22 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
JP2004510762A (ja) 2000-10-02 2004-04-08 メルク　エンド　カムパニー　インコーポレーテッド プレニル−蛋白質トランスフェラーゼの阻害剤
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
CA2465597A1 (en) 2001-11-14 2003-06-12 Ben Zion Dolitzky Amorphous and crystalline forms of losartan potassium and process for their preparation
AU2003237593A1 (en) * 2002-06-05 2003-12-22 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
JP5236664B2 (ja) 2007-02-01 2013-07-17 レスバーロジックス コーポレイション 心血管疾患を予防および治療するための化合物
DK2178870T3 (en) 2007-08-17 2018-10-22 Lg Chemical Ltd INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE
BRPI1015097A2 (pt) 2009-05-29 2019-09-24 Raqualia Pharma Inc uso de um composto, composto, composição farmacêutica, método para tratamento de uma condição ou distúrbio no qual os canais de cálcio do tipo t ou canais de sódio regulados por voltagem estão envolvidos, composto ou um sal farmaceuticamente aceitável do mesmo e uso de um composto ou um sal farmaceuticamente aceitável do mesmo.
WO2014085154A1 (en) 2012-11-27 2014-06-05 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
JP2016531874A (ja) * 2013-09-26 2016-10-13 ファーマケア，インク． オートタキシン阻害剤化合物
CA2959437C (en) 2014-08-27 2018-03-06 The Governing Council Of The University Of Toronto Cannabinoid type 1 receptor modulators
WO2016055517A1 (en) 2014-10-08 2016-04-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel aminopyridine compounds useful as inhibitors of protein prenylation
BR112018001650A2 (pt) 2015-08-27 2018-09-18 Pfizer compostos de heteroarila ou arila fundidos bicíclicos como moduladores de irak4
KR20210116483A (ko) 2018-12-17 2021-09-27 버텍스 파마슈티칼스 인코포레이티드 Apol1 억제제 및 그의 사용 방법
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
TW202140459A (zh) * 2020-02-04 2021-11-01 美商維泰克斯製藥公司 Ａｐｏｌ１抑制劑之固體形式及其使用方法
US11801234B2 (en) * 2020-03-06 2023-10-31 Vertex Pharmaceuticals Incorporated Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
JP2023529216A (ja) 2020-06-12 2023-07-07 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤及びその使用
BR112022025198A2 (pt) 2020-06-12 2022-12-27 Vertex Pharma Formas sólidas do inibidor de apol1 e uso das mesmas
US20230011118A1 (en) 2020-06-12 2023-01-12 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
AU2021333776A1 (en) 2020-08-26 2023-03-16 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same

Also Published As

Publication number Publication date
US11618746B2 (en) 2023-04-04
CA3121910A1 (en) 2020-06-25
JOP20210131A1 (ar) 2023-01-30
AU2019405477A1 (en) 2021-06-24
CO2021009053A2 (es) 2021-08-09
JOP20210129A1 (ar) 2023-01-30
UY38514A (es) 2020-07-31
CN113453760A (zh) 2021-09-28
JP2022515369A (ja) 2022-02-18
DOP2021000116A (es) 2021-09-30
CR20210383A (es) 2021-09-22
JOP20210130A1 (ar) 2023-01-30
MX2021007152A (es) 2021-11-03
KR20210116483A (ko) 2021-09-27
IL283592A (en) 2021-07-29
EP3897833A1 (en) 2021-10-27
AR116913A1 (es) 2021-06-23
US20230271945A1 (en) 2023-08-31
TW202039471A (zh) 2020-11-01
MA54538A (fr) 2021-10-27
PE20212302A1 (es) 2021-12-10
WO2020131807A1 (en) 2020-06-25
CL2021001561A1 (es) 2021-11-26
SG11202105769XA (en) 2021-07-29
BR112021011564A2 (pt) 2021-08-31
US20200377479A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
ECSP21052184A (es) Inhibidores de apol1 y sus métodos de uso
UY38403A (es) Moduladores de la alfa-1 antitripsina
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CL2021003190A1 (es) Inhibidores de tead y usos de los mismos
CO2023002071A2 (es) Compuestos y métodos para el tratamiento de infecciones virales
CO2020016285A2 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
CL2019003627A1 (es) Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628)
BR112017002594A2 (pt) compostos inibidores de cinase de ligação de tank
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
CL2021000669A1 (es) Agentes rnai para inhibir la expresión de 17beta-hsd tipo 13- (hsd17b13), sus composiciones y métodos de uso.
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CR20160419A (es) Nuevos compuestos biciclicos
CR10069A (es) Anticuerpos anti-ox40l y métodos que los utilizan referencia cruzada con solicitudes relacionadas
ECSP099785A (es) Anticuerpos anti-notch1 nrr y sus métodos de uso
UY28342A1 (es) Nuevos compuestos
CO2021013339A2 (es) Degradadores de stat y usos de los mismos
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
CL2017002756A1 (es) Adhesivos acrílicos en emulsión
ECSP21026021A (es) Moduladores de la expresión de pnpla3
ES2609817T3 (es) Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
CO2023014770A2 (es) Degradadores de cdk2 y sus usos
CO2022009691A2 (es) Formulaciones líquidas de tasimelteón y métodos para su uso
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
UY37261A (es) Formulación combinada de tres compuestos antivirales